Amryt Pharma plc (LON:AMYT – Get Free Report) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 143 ($1.89) and traded as high as GBX 155 ($2.05). Amryt Pharma shares last traded at GBX 143 ($1.89), with a volume of 90,726 shares trading hands.
Amryt Pharma Stock Performance
The company has a 50 day moving average of GBX 143 and a 200 day moving average of GBX 143. The company has a debt-to-equity ratio of 66.05, a quick ratio of 1.14 and a current ratio of 1.80. The stock has a market capitalization of £457.11 million and a price-to-earnings ratio of -4.33.
Amryt Pharma Company Profile
Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy.
Read More
- Five stocks we like better than Amryt Pharma
- NYSE Stocks Give Investors a Variety of Quality Options
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Insider Trades May Not Tell You What You Think
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- The Risks of Owning Bonds
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Amryt Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
